ADMA Biologics (NASDAQ:ADMA) released its earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.01, MarketWatch Earnings reports. ADMA Biologics had a negative net margin of 166.01% and a negative return on equity of 98.83%.
NASDAQ ADMA traded up $0.06 during trading hours on Friday, reaching $1.68. The company had a trading volume of 5,627 shares, compared to its average volume of 6,460,805. The stock has a 50-day moving average of $1.80 and a 200 day moving average of $2.08. ADMA Biologics has a 1-year low of $1.45 and a 1-year high of $4.20. The company has a current ratio of 8.47, a quick ratio of 4.24 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $203.74 million, a P/E ratio of -1.88 and a beta of 1.84.
ADMA has been the subject of a number of analyst reports. Raymond James dropped their price objective on shares of ADMA Biologics from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, April 1st. Jefferies Financial Group reissued a “buy” rating and issued a $10.00 price objective on shares of ADMA Biologics in a report on Monday, April 5th. Zacks Investment Research raised shares of ADMA Biologics from a “sell” rating to a “hold” rating in a report on Thursday, May 6th. Finally, Maxim Group reissued a “buy” rating and issued a $6.00 price objective on shares of ADMA Biologics in a report on Friday, March 26th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $7.00.
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.